Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid

Sci Rep. 2023 Oct 24;13(1):18204. doi: 10.1038/s41598-023-45405-8.

Abstract

S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents
  • Humans
  • Mice
  • Staphylococcal Infections* / microbiology
  • Staphylococcal Infections* / therapy
  • Staphylococcus Phages / physiology
  • Staphylococcus aureus* / physiology
  • Synovial Fluid
  • Tissue Plasminogen Activator

Substances

  • Tissue Plasminogen Activator
  • Anti-Bacterial Agents